m+Medelevator.RU
← Поиск публикаций
Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2013

Randomized clinical trial of CO₂ LASER pinpoint irradiation technique versus chemical reconstruction of skin scars (CROSS) in treating ice pick acne scars.

Сравнительное исследованиеСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ahmed Radwa, Mohammed Ghada, Ismail Nader, Elakhras Atef

Аннотация

BACKGROUND: Pinpoint irradiation technique CO₂ LASER and Chemical Reconstruction Of Skin Scars (CROSS) are effective treatments for atrophic acne scars as fractional photothermolysis.

OBJECTIVE: This study was designed to prospectively compare the use of a pinpoint irradiation technique versus TCA CROSS in treating ice pick acne scars.

METHODS: Thirty-two patients with ice pick acne scars were included in this open, label pilot study. Pinpoint irradiation technique by CO₂ LASER and TCA CROSS were applied for the study and control group, respectively. Twenty-eight patients with ice pick acne scars were included in this open, label pilot study. They were randomly assigned to two groups: the first group (14 patients) received pinpoint irradiation by CO₂ LASER as a study group, and the second group (14 patients) received TCA CROSS as a control group. In both treatments, there were four sessions at 3-week interval, and 3 months of follow up.

RESULTS: There were statistically significant difference in acne scar severity index and qualitative scarring grading system in the improvement results between the study and control groups (p < 0.05).

CONCLUSION: Pinpoint irradiation technique by CO₂ LASER is safe and more effective than TCA CROSS technique. Clinical improvement was achieved in all 14 patients without dramatic adverse effects.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты